GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GH Research PLC (GHRS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 178 K | -77,446,000 | 7.33 M | 226.3 M | 164.09 M |
| 2022 | 90 K | -165,955,000 | 4.55 M | 254.36 M | 168.54 M |
| 2021 | 48 K | -276,776,000 | 2.75 M | 279.92 M | 279.84 M |
| 2020 | -5,895,000 | 246 K | 5.91 M | 5.91 M | |
| 2019 | -498,000 | 104 K | 504 K | 504 K |